A Phase III trial of XRx-008 in autosomal dominant polycystic kidney disease patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Apr 2023 According to XORTX media release, company is looking forward to upcoming meeting with the FDA on May 1, 2023 to discuss our planned phase 3 clinical program for XORLO.
14 Mar 2023 According to XORTX media release, this clinical data to support a future "Accelerated Approval" new drug application (NDA) submissions to the FDA and European Medicines Agency (EMA).
14 Mar 2023 According to XORTX media release, company has announced the submission of a Type D meeting request to the USFDA for revised clinical trial protocol for this study and a response setting the date for a virtual meeting on 1st May 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com